Formal diagnosis of essential thrombocythemia (ET) requires a plateletcount of≥450×109/L that is associated with morphologic or molec-ular evidence of an underlying myeloproliferative neoplasm (MPN)that is not otherwise classified as polycythemia vera (PV), prefibroticor overt primary myelofibrosis (PMF).1Approximately 22% of patientswith ET present with a platelet count of≥1000×109/L, which is arbi-trarily referred to as extreme thrombocytosis (ExT).2,3The particularpresentation is quite unnerving for both patients and their physiciansbecause of assumed increased risk for thrombotic complications. Inthis regard, despite the lack of supporting evidence, some physiciansare inclined to institute cytoreductive therapy in the presence of ExT,in otherwise low-risk ET (defined by the absence of thrombosis historyand age≤60 years).

Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies / Tefferi A.; Szuber N.; Pardanani A.; Hanson C.A.; Vannucchi A.M.; Barbui T.; Gangat N.. - In: AMERICAN JOURNAL OF HEMATOLOGY. - ISSN 0361-8609. - ELETTRONICO. - 96:(2021), pp. E182-E184. [10.1002/ajh.26137]

Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies

Vannucchi A. M.;
2021

Abstract

Formal diagnosis of essential thrombocythemia (ET) requires a plateletcount of≥450×109/L that is associated with morphologic or molec-ular evidence of an underlying myeloproliferative neoplasm (MPN)that is not otherwise classified as polycythemia vera (PV), prefibroticor overt primary myelofibrosis (PMF).1Approximately 22% of patientswith ET present with a platelet count of≥1000×109/L, which is arbi-trarily referred to as extreme thrombocytosis (ExT).2,3The particularpresentation is quite unnerving for both patients and their physiciansbecause of assumed increased risk for thrombotic complications. Inthis regard, despite the lack of supporting evidence, some physiciansare inclined to institute cytoreductive therapy in the presence of ExT,in otherwise low-risk ET (defined by the absence of thrombosis historyand age≤60 years).
2021
96
E182
E184
Tefferi A.; Szuber N.; Pardanani A.; Hanson C.A.; Vannucchi A.M.; Barbui T.; Gangat N.
File in questo prodotto:
File Dimensione Formato  
American J Hematol - 2021 - Tefferi - Extreme thrombocytosis in low‐risk essential thrombocythemia Retrospective review of.pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: DRM non definito
Dimensione 1.44 MB
Formato Adobe PDF
1.44 MB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1257170
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 11
social impact